Cas:4232-72-8 (2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine manufacturer & supplier

We serve Chemical Name:(2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine CAS:4232-72-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine

Chemical Name:(2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine
CAS.NO:4232-72-8
Synonyms:2,3,5,6-Tetrafluor-4-methylphenylhydrazin;2,3,5,6-Tetrafluor-p-tolylhydrazin;2,3,5,6-tetrafluoro-4-methylphenylhydrazine;MFCD00012367;(4-METHYL-2,3,5,6-TETRAFLUOROPHENYL)HYDRAZINE
Molecular Formula:C7H6F4N2
Molecular Weight:194.13000
HS Code:

Physical and Chemical Properties:
Melting point:83-85ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.05000
Exact Mass:194.04700
LogP:2.61030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,3,5,6-Tetrafluor-4-methylphenylhydrazin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-METHYL-2,3,5,6-TETRAFLUOROPHENYL)HYDRAZINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3,5,6-Tetrafluor-4-methylphenylhydrazin Use and application,2,3,5,6-Tetrafluor-4-methylphenylhydrazin technical grade,usp/ep/jp grade.


Related News: There are also new directives that relate to US citizens. (2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine manufacturer The FDA said its decision allows for the J&J doses to be used in the United States or exported. T (2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine supplier The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. (2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine vendor The FDA said its decision allows for the J&J doses to be used in the United States or exported. T (2,3,5,6-Tetrafluoro-4-methylphenyl)hydrazine factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.